Clinical and pathogenetic aspects of the purine metabolism state in diabetes mellitus (review of literature and own observations)

Authors

  • Cherniaieva A. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Karachentsev Y. I. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Kravchun N. A. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
  • Tykhonova T. M. SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2018.4.08

Keywords:

diabetes mellitus, uric acid, purine metabolism

Abstract

In recent years attention has been paid on the state of purine metabolism (PM) in diabetes mellitus (DM) and the possible role of disturbances in the metabolism of uric acid (UA) in the manifestation and progression of this endocrine pathology. Up today it has been proven that the imbalance of UA is a risk factor for the occurrence of such conditions and disorders, which are usually combined with DM, namely: cardiovascular diseases, arterial hypertension, chronic kidney disease and vascular lesions. In addition, hyperuricemia (HUE) is considered as a component of the metabolic syndrome (MS) and the relationship of HUE with insulin resistance is revealed. Despite a significant number of studies on the state of the PM in patients with MS and with type 2 diabetes, there are a number of issues that need to be resolved, and data on the status of the PM in type 1 diabetes are only isolated. Based on a examination of 95 patients with DM, metabolic disorders of UA were detected in 28.42 % of DM patients, including 25.64 % of patients with type 1 DM, 36 % of patients with type 2 DM and 25.81 % of patients with type 2 DM with development of absolute insulin dependence. There are no significant differences in the frequency of imbalance of PM depending on the type of DM and insulin dependence. In patients with DM asymptomatic HUE was observed, so the absence of arthritis is not a criterion for excluding metabolic disorders of UA with diabetes. In patients with type 1 DM metabolic disturbances of UA are associated with complicated forms of the disease, in particular, with the development of diabetic nephropathy and diabetic foot syndrome.

References

World Health Organization International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia : report of a WHO/IDF consultation, Geneva, 2006: 50 р.

Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Diabetes 2013; 62 (10): 3307-3315. doi: http://doi.org/10.2337/db12-1814.

Khemka VK, Bagchi D, Ghosh A, et al. Sci World J 2013; 2013: 404320. doi: http://doi.org/10.1155/2013/404320.

Hodzhakuliev BG, Begencheva GO, Ahmedova DM, et al. Molodoj Uchenyj 2014; 18: 178-184.

Desideri G, Castaldo G, Lombardi A, et al. Eur Rev Med Pharmacol Sci 2014; 18 (9): 1295-1306.

Zhdan VM, Bobir'ov VM, Kapustjans'ka AA, et al. Semejnaja Medicina 2016; 2: 44-46.

Norvik JV. A dissertation for the degree of Philosophiae Doctor 2017: 99 р.

Koval' SN, Bozhko VV, Mysnichenko OV. Ukr Revmatol Zhurn 2009; 38 (4): 75-80.

Viazzi F, LeonciniG, Pontremoli R. Reumatismo 2012; 63 (4): 253-262. doi: http://doi.org/10.4081/reumatismo.2011.253.

Yoo TW, Sung KC, Shin HS, et al. Circ J 2005; 69 (8): 928-933.

Billiet L, Doaty S, Katz JD, Velasquez MT. ISRN Rheumatology 2014; Article ID 852954: 7 p. doi: http://doi.org/10.1155/2014/852954.

Ekpenyong C, Akpan E. Am J Intern Med 2014; 6 (2): 113-130. doi: http://doi.org/10.11648/j.ajim.20140206.15.

Bojko ER, Ovechkin AO, Kaneva AM, Potolicyna NN. Ateroskleroz 2011; 7 (1): 26-30.

Wannamethee SG. Curr Hypertens Rep 2001; 3 (3): 190-196.

Titov VN, Bojcov SA, Urazalina SZh, et al. Ateroskleroz i dislipidemii 2013; 11 (2): 31-39.

Prashanthkumar G, Nagendra S, Kashinath RT. Global J Med Res: F Diseases 2015; 15 (2): 26-30.

Alderman MH. Curr Hypertens Rep 2001; 3 (3): 184-189.

Jia G, Aroor AR, Whaley-Connell AT, Sowers JR. Curr Hypertens Rep 2014; 16 (6): 434. doi: http://doi.org/10.1007/s11906-014-0434-z.

Shuba NM. Ukr Revmatol Zhurn 2013; 52 (2): 14-22.

Synjachenko OV, Ignatenko GA, Muhin IV. Medycyna zaliznychnogo transportu Ukrai'ny 2004; 1: 96-100.

Li C, Hsieh MC, Chang SJ. Curr Opin Rheumatol 2013;25 (2): 210-216. doi: http://doi.org/10.1097/BOR.0b013e32835d951e.

Bonakdaran S, Kharaqani B. Curr Diabetes Rev 2014; 10 (20): 113-117.

Al-Daghri NM, Al-Attas OS, Wani K, et al. Sci Reports 2017;7: 12104. doi: http://doi.org/10.1038/s41598-017-12085-0.

Markina NV. Rol' insulinorezistentnosti v razvitii jendotelial'noj disfunkcii i narushenii purinovogo obmena,Moskva, 2009: 136 p.

Chou P, Lin KC, Lin HY, Tsai ST. J Rheumatol 2001;28 (3): 571-576.

Chen L, Zhu W, Chen Z, et al. J Zhejiang Univ Sci B 2007; 8 (8): 593-598.

Jakovenko AJu. Osoblyvosti diagnostyky ta likuvannja metabolichnogo syndromu u pojednanni z giperurykemijeju, Kyi'v, 2009: 21 p.

Nakanishi N, Okamoto M, Yoshida H, et al. Eur J Epidemiol 2003; 18 (6): 523-30.

Van der Schaft N, Brahimaj A, Wen K, et al. PLoS ONE. 2017; 12 (6): e0179482. doi: http://doi.org/10.1371/journal.pone.0179482.

Krishnan E, Pandya BJ, Chung L, et al. Am J Epidemiol 2012; 176 (2): 108-116.

So A, Thorens B. J Clin Invest 2010; 120 (6): 1791-1799. doi: http://doi.org/10.1172/JCI42344.

Barskova VG, Eliseev MS, Zilov AV, Nasonov EL. Ozhirenie i Metabolizm 2007; 1: 19-23.

Korpachev VV, Mosendz IO, Gurina NM, Shuprovych AA. Mezhdunar jendokrinol zhurn 2006; 2: 42-46.

Chang YH, Lei CC, Lin KC, et al. Diabetes Metab Res Rev 2016; 32 (6): 557-564. doi: http://doi.org/10.1002/dmrr.2768.

Teodorovich OV, Ametov AS, Bova FS. RMZh 2008; 15: 985.

Latif H, Iqbal A, Rathore R, Butt NF. Pakistan J Med Sci 2017; 33 (6): 1371-1375. doi: http://doi.org/10.12669/pjms.336.13224.

Facchini F, Ida Chen YD, Hollenbeck CB, Reaven GM. JAMA 1991; 266 (21): 3008-3011.

Bandaru P, Shankar A. Int J Endocrinol 2011; 2011: 604715. doi: http://doi.org/10.1155/2011/604715.

Gurina NM, Korpachev VV, Shuprovych AA, et al. Endokrynologija 2016; 21 (1): 10-15.

Madjanov IV. Osobennosti purinovogo obmena na jetapah razvitija i progressirovanija saharnogo diabeta (diagnosticheskie, patogeneticheskie i lechebnye aspekty), Moskva, 1999: 45 p.

Mihajlichenko VJu, Stoljarov SS, Staryh AA. Sovremennye problemy nauki i obrazovanija 2015; 5, available at:

http://www.science-education.ru/ru/article/view?id=21551.

Meyramov GG, Kohnert KD, Kikimbaeva AA, et al. Bull Exp Biol Med 2015; 159 (5): 680-684. doi: http://doi.org/10.1007/s10517-015-3046-y.

Donga E, Dekkers OM, Corssmit EP, Romijn JA. Eur J Endocrinol 2015; 173 (1): 101-109. doi: http://doi.org/10.1530/EJE14-0911.

Sauer AV, Brigida I, Carriglio N, Aiuti A. Front Immunol 2012; 3: 265. doi: 10.3389/fimmu.2012.00265.

Lytvyn Y, Škrtić M, Yang GK, et al. Am J Physiol Renal Physiol 2015; 308 (2): F77-83. doi: http://doi.org/10.1152/ajprenal.00555.2014.

Ficociello LH, Rosolowsky ET, Niewczas MA, et al. Diabetes Care 2010; 33 (6): 1337-1343. doi: http://doi.org/10.2337/dc10-0227.

Bjornstad P, Maahs DM, Rivard CJ, et al. Acta Diabetol 2014; 51 (5): 783-791. doi: http://doi.org/10.1007/s00592-014-0611-1.

Barskova VG, Eliseev MS, Kudaeva FM, et al. Klinich medicina 2009; 7: 41-46.

Iljuhina OB, Madjanov IV. Prakt medicina 2010; 43: 122-124.

Downloads

Published

2021-08-17

How to Cite

Cherniaieva, A. A. ., Karachentsev, Y. I. ., Kravchun, N. A. ., & Tykhonova , T. M. . (2021). Clinical and pathogenetic aspects of the purine metabolism state in diabetes mellitus (review of literature and own observations). Problems of Endocrine Pathology, 66(4), 75-84. https://doi.org/10.21856/j-PEP.2018.4.08

Most read articles by the same author(s)

<< < 1 2 3 > >>